Saluda Medical serves customers in the United States.

Evoke is designed to optimize pain relief by measuring and recording each patient's unique response to stimulation, and then making millions of real-time adjustments per day to maintain a consistent level of therapy. An email containing a verification link has been sent to {{verificationEmail}}. Saluda Medical is a privately held company with headquarters in Artarmon, New South Wales, Australia and offices in Bloomington, MN, USA and Harrogate, UK. All Rights Reserved. The market leader in this sector is ASX-listed ResMed Inc. (CHESS) (ASX: RMD) and the potential for innovative new therapies to challenge its existing medical … Media Contact: Kirsten Thomas +1 (508) 280-6592 kthomas@theruthgroup.com The Company develops neuromodulation technology that improve the treatment of chronic pain, epilepsy, and other debilitating disorders. Click for restrictions. The interviewers were late for 9 minutes and asked only a few questions related to C#.NET. profile, My dashboard. To learn more, visit www.saludamedical.com and connect with us on LinkedIn at www.linkedin.com/company/saluda-medical/. Level 1, 407 Pacific Highway Please log in with your existing credentials, My Cision Distribution 888-776-0942

I interviewed at Saluda Medical (Sydney (Australia)) in August 2017. Saluda Medical is a global neuromodulation company leading the development and commercialization of data-driven, personalized therapies for patients with chronic pain. Market data is provided and copyrighted by Thomson Reuters and Morningstar. All rights reserved. Saluda Medical is a privately held company with headquarters in Artarmon, New South Wales, Australia and offices in Bloomington, MN, USA and Harrogate, UK.

Ltd. operates as a biotechnology company. As President, Mr. Schuermann will be responsible for the global commercial and clinical strategy and execution of corporate objectives. In the EU, Evoke is CE Marked and commercially available.

SCS treats the condition by stimulating the spinal cord and altering the transmission of pain signals to the brain. Strengthens corporate leadership as company moves toward global commercialization.

Chris is currently chairman of Cohda Wireless, Saluda Medical, Booktopia, Capital Markets Technologies and Significance Systems and is involved in a number of other technology companies. They may concern more about what you already know instead of …

The company's first product, Evoke®, is a closed-loop spinal cord stimulator (SCS) system designed to treat chronic pain, a condition that affects more than 546 million people globally. Saluda Medical is a global neuromodulation company leading the development and commercialization of data-driven, personalized therapies for patients with chronic pain. In the U.S., Evoke is currently under investigation through the first double-blinded, randomized, controlled U.S. pivotal study in SCS and is not commercially available. Mr. Schuermann stayed on post-acquisition as Vice President and General Manager of Medtronic's Mechanical Circulatory Support Division, a newly formed business unit in the Cardiac & Vascular Group. To learn more, visit www.saludamedical.com and connect with us on LinkedIn at www.linkedin.com/company/saluda-medical/. He is the former chairman of DEXUS Property Group (ASX:DXS) and FlexiGroup (ASX:FXL).

Artarmon, NSW 2064 Prior to HeartWare, he held a number of senior leadership roles at Boston Scientific and started his medical device career at Sherwood Medical. John Parker, CEO of Saluda Medical, commented, "Jim and Bob bring to Saluda a wealth of knowledge, experience, and successful track records. The Company develops neuromodulation technology that improve the treatment of chronic pain, epilepsy, and other debilitating disorders. Ltd. operates as a biotechnology company. Interview.

from 8 AM - 9 PM ET, Copyright © 2020 PR Newswire Association LLC. Mr. Gaffney's previous experience includes key management positions in several start-ups as well as established companies, including President and Chief Executive Officer of SacraMed, Vice President of Operations at InCube Labs, Chief Operating Officer at Spinal Modulation where he led the successful acquisition by St. Jude Medical, and Vice President of Operations at Satiety. Please choose another, Invalid password: must not contain more than 3 consecutive identical characters, Invalid password: must not contain more than 3 consecutive sequential characters, The password cannot contain the user name, given name, or family name. Market data is provided and copyrighted by Thomson Reuters and Morningstar. Saluda Medical is a global neuromodulation company leading the development and commercialization of data-driven, personalized therapies for patients with chronic pain. As COO, Mr. Gaffney will be responsible for Saluda Medical's manufacturing, operations, and product development. Saluda Medical is a global neuromodulation company leading the development and commercialization of data-driven, personalized therapies for patients with chronic pain.

Mr. Schuermann brings over 25 years of extensive healthcare and medical device leadership experience to Saluda Medical. View today’s ASX share price, options, bonds, hybrids and warrants.

View announcements, advanced pricing charts, trading status, fundamentals, dividend information, peer … Mr. Schuermann and Mr. Gaffney will report to Chief Executive Officer John Parker.

ARTARMON, Australia, June 9, 2020 /PRNewswire/ -- Saluda Medical Pty Limited ("Saluda Medical"), a global neuromodulation company leading the development and commercialization of data-driven, personalized therapies for patients with debilitating neurological disorders, today announced the key leadership appointments of Jim Schuermann as President and Robert Gaffney as Chief Operating Officer.

Prior to Avedro, he was Senior Vice President of Sales and Marketing at HeartWare, which had its initial public offering on the ASX and later was listed on the NASDAQ until it was acquired by Medtronic.